|
Thrombocytopenia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Specific VEGFR-TKIs; pazopanib, regorafenib, and nintedanib were associated with a decrease risk of remaining free of an arterial thrombotic event (RR 0.96; 95%CI:0.93-0.99), thrombocytopenia (RR 0.91; 95%CI:0.89-0.93), and bleeding (RR 0.96; 95%CI:0.93-0.99) respectively.
|
31698959 |
2020 |
|
High output heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Development of AVMs and associated progression to HOHF in the absence of endothelial ENG was attenuated by targeting VEGF signalling with an anti-VEGFR2 antibody.
|
31805812 |
2020 |
|
Metastatic Childhood Soft Tissue Sarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
|
31786466 |
2020 |
|
Iodine deficiency syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results support a genetic interaction between the VEGF-A rs3025039 and VEGFR-2 rs2071559 polymorphisms as a predictor of the risk to develop nodular goiter in subjects coming from an area with mild iodine deficiency.
|
31376092 |
2020 |
|
Metastatic Soft Tissue Sarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
|
31786466 |
2020 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Protein expression analysis revealed that the vascular endothelial growth factor receptor 2 (VEGFR2) score was significantly higher in the sestamibi-positive cohort compared to sestamibi-negative adenomas (P = .038).
|
31291025 |
2019 |
|
Aortic Valve Stenosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with severe AS had significantly elevated numbers of total circulating EPC-OCNs, including the EPC-OCN subtypes CD133<sup>+</sup>/OCN<sup>+</sup>, CD34<sup>+</sup>/CD133<sup>+</sup>/OCN<sup>+</sup>, and CD133<sup>+</sup>/KDR<sup>+</sup>/OCN<sup>+</sup>, compared with those with mild AS.
|
30947832 |
2019 |
|
Intracranial Aneurysm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our findings demonstrated that decreased expression of circRNA_0020397 in IA may contribute to the decreased VSMC proliferation via increasing miR-138 expression and subsequently decreasing KDR expression.
|
31096819 |
2019 |
|
Muscular Dystrophy, Duchenne
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we evaluated the effect of α-methyl-prednisolone (PDN) on the expression of the angiogenic marker HIF1α, VEGFA and VEGFR-2 (FLK1) in correlation with PKC expression in the brain of mdx mouse, an experimental model of DMD.
|
30711624 |
2019 |
|
Fenestration (morphologic abnormality)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Nevertheless, PLVAP in fetal LSEC (fenestrations with diaphragms) associated with LYVE-1 (lymphatic vessel endothelial hyaluronan receptor 1), neuropilin-1 and VEGFR2 (vascular endothelial growth factor receptor 2), whereas in the adult LSEC (fenestrations without diaphragms) these complexes disappeared.
|
31666588 |
2019 |
|
Fibrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we firstly found that patients with sorafenib resistance showed no significant change in rapidly accelerated fibrosarcoma and VEGFR expression levels compared with sorafenib sensitive patients.
|
31087496 |
2019 |
|
Gastritis, Atrophic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, compared with the control group, the protein and gene expression of COX-2, HIF-1<i>α</i>, VEGFR1, and VEGFR2 in gastric tissues of pylorus was obviously increased and the serum PGE2 level was significantly deceased in CAG rats, which could be significantly counteracted by WQD administration.
|
31320912 |
2019 |
|
Hypercholesterolemia, Familial
|
0.010 |
Biomarker
|
disease |
BEFREE |
VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia.
|
30991288 |
2019 |
|
Nephroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report a case of Wilms tumor in a 24-year-old woman who was effectively treated with apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2.
|
30985306 |
2019 |
|
Neurilemmoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we show an exploratory clinical study of VEGFRs peptide vaccine in seven patients with progressive NF2-derived schwannomas.
|
31848332 |
2019 |
|
Neurofibromatosis 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we show an exploratory clinical study of VEGFRs peptide vaccine in seven patients with progressive NF2-derived schwannomas.
|
31848332 |
2019 |
|
Periodontitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, there was a proportional increase in CD133+/KDR+ levels with a progressive increase in number of teeth (<i>p</i>-trend < 0.001), while there was a proportional decrease in CD133+/KDR+ levels with a proportional increase in clinical attachment level (CAL, <i>p</i>-trend = 0.003), probing depth (PD, <i>p</i>-trend = 0.007), and bleeding sites (bleeding on probing (BOP), <i>p</i>-trend < 0.001) as an extent measure of periodontitis.
|
31817862 |
2019 |
|
Peripheral Neuropathy
|
0.010 |
Biomarker
|
group |
BEFREE |
Risk of peripheral neuropathy with VEGFR-TKIs was higher even when they were compared against control (either placebo or standard chemotherapeutic agents) (RR 1.08; 95% CI 1.01-1.15, <i>p</i> = 0.03).
|
31167931 |
2019 |
|
Respiratory Distress Syndrome, Adult
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study suggested that VEGF is involved in FE-induced ARDS via the VEGFR-2 and MAPK cascades, which induce IL-1β release and iNOS upregulation.
|
31406128 |
2019 |
|
Werner Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Knock-down of OGG1, which does not interact with WRN, does not influence motility but increases the mRNA expression of E-selectin, ICAM, VCAM, CCL2 and VEGFR and stimulates adhesion.
|
30413344 |
2019 |
|
Pyogenic granuloma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment.
|
31776151 |
2019 |
|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared with the AMI group, BHD promoted the expression of Cav-1, VEGF, VEGFR2, and p-ERK in the infarction border zone after AMI.
|
31178960 |
2019 |
|
Gallbladder Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The efficacy of apatinib, an highly potent and selective oral inhibitor of VEGFR-2 tyrosine kinase, for refractory advanced GBC has not yet been clarified.
|
31788447 |
2019 |
|
Coronary Stenosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Homozygous GG genotype and G allele of VEGFR2 rs2071559 polymorphism were associated with decreased risk of developing coronary artery stenosis.
|
30991288 |
2019 |
|
Parathyroid Adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It is hypothesized that VEGFR-2 overexpression in parathyroid adenomas increases vascular permeability resulting in a higher uptake of sestamibi.
|
31291025 |
2019 |